HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SMMT
Summit Therapeutics Inc.
There isn't enough reported data to score SMMT yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SMMT Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Weak | |
| Unavailable | |
| Unavailable |
SMMT's profitability is currently weak. There isn't enough data to rate its revenue, cash flow and balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SMMT PE Valuation
SMMT has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SMMT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Stable | |
| -- | |
| Limited | |
| Low |
Analysts expect SMMT's losses to grow, with revenue holding steady. However, they disagree widely on these estimates.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over SMMT on earnings, with more consistent year-over-year improvement.
SMMT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.06 | +$0.18 |
| Q2 2026 | -$1.11 | -$0.10 |
| Q1 2026 | -$1.59 | -$1.25 |
| Q4 2025 | -$1.44 | -$1.13 |
| Q3 2025 | -$1.24 | -$0.96 |
| Q2 2025 | -$1.01 | -$0.78 |
| Q1 2025 | -$0.34 | -$0.18 |
| Q4 2024 | -$0.31 | +$1.22 |
SMMT lost $1.06 per share over the past year, a smaller loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
SMMT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2022 | $220K | -83% |
| Q2 2022 | $235K | +312% |
| Q1 2022 | $250K | +30% |
| Q4 2021 | $251K | +36% |
| Q3 2021 | $1.3M | +623% |
SMMT's revenue has slid since its 2021 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2022 | -7700% | -6211 points |
| Q2 2022 | -5401% | +36231 points |
| Q1 2022 | -8863% | -49 points |
| Q4 2021 | -10377% | -3054 points |
| Q3 2021 | -1489% | +8576 points |
| Q2 2021 | -41632% | N/A |
| Q1 2021 | -8814% | N/A |
| Q4 2020 | -7324% | N/A |
SMMT's operating margin was −7700% last quarter, down 6211 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SMMT on cash generation, producing positive trailing cash flow while its opponent burns cash.
SMMT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$160.2M | -$67.1M |
| Q2 2026 | -$142M | -$75.3M |
| Q1 2026 | -$122.5M | -$60.9M |
| Q4 2025 | -$102.1M | -$53.4M |
| Q3 2025 | -$93.2M | -$62.8M |
| Q2 2025 | -$66.7M | -$33.7M |
| Q1 2025 | -$61.6M | -$31.5M |
| Q4 2024 | -$48.7M | -$29.2M |
SMMT has burned cash in almost every quarter: −$527M over the past year, against −$270M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SMMT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SMMT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +2.6% | +20M shares |
| 1 year | +7.4% | +54.8M shares |
| 3 years | +14% | +100M shares |
| 5 years | +781% | +708M shares |
SMMT has 798M diluted shares, up 7.4% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SMMT Net Leverage
SMMT's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SMMT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 47.2 | Neutral |
| Stochastic | 53.3 | Neutral |
SMMT's weekly RSI is 47 (neutral) and its Stochastic is 53 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SMMT PE vs Healthcare Sector
SMMT has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SMMT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $15.9 | 5.5% below |
| 20 week MA | $15.3 | 1.4% below |
| 50 week MA | $16.3 | 7.8% below |
| 100 week MA | $19.0 | 21% below |
| 200 week MA | $12.6 | 19% above |
SMMT has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SMMT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.55 | $5.70 | +268% |
| 2021 | $5.70 | $3.03 | -47% |
| 2022 | $3.03 | $3.67 | +21% |
| 2023 | $3.67 | $2.61 | -29% |
| 2024 | $2.61 | $18.2 | +598% |
| 2025 | $18.2 | $18.1 | -0.4% |
| 2026 YTD | $18.1 | $15.1 | -17% |
SMMT has the edge over HIMS on returns for 2026, with the stronger performance.